Merck Acquires EyeBio in $3 Billion Deal to Boost Eye Disease Treatments
TL;DR Summary
Merck is re-entering the ophthalmology drug market with a $1.3 billion upfront cash acquisition of EyeBio, marking its return to the lucrative eye disease sector after a decade-long absence.
- Merck returns to lucrative eye disease market in up to $3B deal for EyeBio Endpoints News
- Merck Reaches $1.3 Billion Deal for Eye-Drug Company EyeBio The Wall Street Journal
- Merck signs $3bn deal for Kate Bingham-backed eye disease biotech Financial Times
- Merck could pay up to $3 billion to boost its retinal disease candidate pipeline MarketWatch
- Merck To Pay as Much as $3 Billion for Eye Treatment Startup Bloomberg
Reading Insights
Total Reads
0
Unique Readers
1
Time Saved
0 min
vs 1 min read
Condensed
48%
56 → 29 words
Want the full story? Read the original article
Read on Endpoints News